IMU
Director Trades
| Date | Director | Value |
|---|
Company News
Imugene Raises $37.5m to Advance Azer-Cel Clinical Trials for Refractory Lymphoma Patients
Imugene (ASX: IMU) has received firm commitments for a $37.5 million capital raising to advance the development of off-the-shelf (allogeneic) CAR-T drug azer-cel for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The company will raise an initial $22.5 million from the placement of 68.2 million shares priced at $0.33 each, a 22.4% discount to […]
Imugene reports promising Azer-cel results for advanced lymphoma patients in Phase 1b trial
Imugene (ASX: IMU) has announced positive results from a Phase 1b clinical trial using lead candidate azer-cel on patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Ten enrolled patients had previously undergone up to five lines of cancer treatment for the non-Hodgkin’s lymphoma, including autologous chimeric antigen receptor (CAR) T-cell therapy—all of which […]
Australian biotech sector tipped for strong growth
Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it. International research firm KPMG recently forecast Australia could generate over $15 billion in exports to the United States and create 34,000 high-skilled jobs by accelerating US-Australia biotechnology collaboration. Australia’s $1.2b biotech industry currently ranks fifth in the world in terms […]
Imugene’s onCARlytics clears Phase 1 milestone in solid tumour therapy trial
Clinical stage immuno-oncology company Imugene (ASX: IMU) has confirmed that a Phase 1 clinical trial of lead drug candidate onCARlytics has cleared its first cohort within the intra-tumoural monotherapy arm of the study. Known as OASIS, the first-in-class trial combines a CD19-expressing oncolytic virus that flags solid tumours for attack by CD19-targeting therapeutics such as […]
Imugene doses first patient in onCARlytics trial targeting cancer with novel approach
Clinical stage immuno-oncology company Imugene (ASX: IMU) has dosed the first patient in the intravenous monotherapy arm of its Phase 1 clinical trial of CD19 oncolytic virotherapy drug candidate onCARlytics. Known as OASIS, the first-in-class clinical trial is targeting adult patients in the US with advanced or metastatic solid tumours. It aims to evaluate the […]
Imugene’s novel cancer treatment enters new phase in MAST trial
Imugene (ASX: IMU) continues to expand its phase 1 MAST (metastatic advanced solid tumours) trial evaluating the safety of novel cancer-killing virus CF33- hNIS (VAXINIA). The clinical stage immuno-oncology company has now successfully increased dose rates with the first patients in each arm of the higher dose cohort as part of the phase 1 study. […]
Imugene reports positive outcomes in novel virus trial against advanced cancers
Clinical stage immuno-oncology company Imugene (ASX: IMU) has obtained positive initial results from a clinical trial investigating its potential treatment of tumours with a unique cancer-killing virus. The phase 1 MAST (metastatic advanced solid tumours) trial is currently evaluating the safety and efficacy of the novel cancer-killing virus CF33-hNIS (VAXINIA). The multi-centre phase 1 MAST […]
Imugene and US firm NeoImmuneTech partner to develop next-gen cancer therapy
Imugene (ASX: IMU) and NeoImmuneTech have formed an Australian-US collaboration to further investigate the potential to combine two promising cancer treatments. Sydney-headquartered clinical stage immuno-oncology company Imugene and NeoImmuneTech, a T-cell-focused biopharmaceutical company based in Maryland, USA, have come together to evaluate Imugene’s allogeneic CAR T azer-cel in combination with NeoImmuneTech’s proprietary immune T-cell amplifier […]
Market wrap: resilient local bourse rises on takeovers and higher iron ore prices
A resilient Australian share market bounced higher on Friday, shrugging off earlier losses on the back of potential takeover action and the chances that US interest rate have peaked. By the close of trade the ASX 200 closed up 0.3% or 21.6 points higher at 7194.9 points, a 1.7% rise for the week, representing the […]
Doorway into Europe opens for Imugene with PD1-Vaxx cancer vaccine patent grant imminent
Imugene (ASX: IMU) has achieved another significant international approval milestone with the company receiving notification from the European Patent Office that the grant of a patent for its PD1-Vaxx cancer vaccine is imminent. The company has also announced plans for a new set of trials in the UK and Australia. Official granting of the new […]
